Top Story

FDA places full clinical hold on pacritinib

February 10, 2016

The FDA has placed a full clinical hold on studies that involve pacritinib, an oral tyrosine kinase inhibitor in development for the treatment of patients with myelofibrosis.

Under the full clinical hold, all patients currently undergoing treatment with pacritinib (CTI BioPharma) must discontinue use immediately. No patients can be enrolled into trials or start pacritinib as initial or crossover treatment.

In the Journals

Palliative care reduces financial burden of patients with advanced cancer, comorbidities

February 10, 2016
The immediate initiation of palliative care among hospitalized patients with incurable cancers and chronic comorbid conditions resulted in significant hospital cost…
EditorialPublication Exclusive

The year of living dangerously

HemOnc Today, February 10, 2016
Derek Raghavan, MD, PhD
The turmoil of December and early January has died down, and I have had time to think about the upcoming year, which seems to offer the possibility of being a year that…
Pharmacology ConsultPublication Exclusive

Biosimilars may expand drug access, reduce costs, but still much to learn

HemOnc Today, February 10, 2016
Jai N. Patel, PharmD
Cancer is the major indication for six of the 10 best-selling biological products.Meanwhile, the cost of cancer biologics in the United States has doubled from 2006 to…
Cover StoryPublication Exclusive

Gene therapy represents ‘new paradigm’ for treatment of hematologic disorders

HemOnc Today, February 10, 2016
Researchers in hematology have long believed that gene therapy may provide a pathway to more effectively treat chronic genetic hematologic disorders, with the potential…
More News Headlines »

The Patient with Non-Small Cell Lung Cancer

No commercial support for this activity.

The management of non-small cell lung cancer (NSCLC) has evolved in the past decade, as advances are made in diagnosis…
More »
Meeting News CoverageVideo

VIDEO: Negative ACCORD trial results reinforce standard of care for rectal cancer

January 27, 2016
More »

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty-five percent of lung cancers are non-small…
More »
Current Issues
View the Current Issue
HemOnc Today